Barillari Giovanni

prof. Giovanni Barillari

Titoli di studio

1983: Laurea in Medicina e Chirurgia, Università "La Sapienza" di Roma.

1987: Specializzazione in Patologia Generale, Università "La Sapienza” di Roma.

1991: Master in Biologia Cellulare e Molecolare, Foundation for Advanced Education in Sciences, National Institutes of Health (NIH), Bethesda (MD), USA.

Cronologia d’impiego

1983-1987: specializzando, Istituto di Patologia Generale, Università "La Sapienza" di Roma.

1987-1988: ricercatore ospite del Dipartimento di Medicina Sperimentale, Università "Tor Vergata" di Roma.

1988-1993: ricercatore ospite del Laboratorio di Biologia della Cellula Tumorale, National Cancer Institute, NIH, Bethesda (MD), USA.

1993-2000: ricercatore universitario presso il Dipartimento di Medicina Sperimentale, Università "Tor Vergata" di Roma.

2000-2006: professore associato di Patologia Generale, Facoltà di Medicina e Chirurgia, Università "Tor Vergata" di Roma.

dal 2006: professore ordinario di Patologia Clinica, Facoltà di Medicina e Chirurgia, Università "Tor Vergata" di Roma.

Attività Didattica relativa all’anno accademico 2010-11

Corsi di Laurea Magistrale: insegnamenti “Patologia Generale” e “Patologia Clinica” nel Corso di Laurea in Odontoiatria e Protesi Dentaria.

Corsi di Laurea Sanitaria Triennale: insegnamento “Patologia Clinica Applicata”, nel Corso di Laurea in Igiene Dentale; insegnamento “Patologia Clinica”, nel Corso di Laurea in Tecniche di Fisiopatologia Cardiocircolatoria.

Scuole di Specializzazione: insegnamento “Patologia Clinica” nella Scuola di Specializzazione in Oncologia ed in quella in Geriatria.

Attività Istituzionali

Coordinatore della Commissione Didattica della Facoltà di Medicina e Chirurgia dell’Università degli Studi “Tor Vergata” di Roma.

Attività Scientifica

L’attività di ricerca è concentrata sui meccanismi alla base della progressione neoplastica, sull’individuazione di marcatori diagnostici e prognostici di neoplasia, e sull’analisi degli effetti molecolari di nuovi farmaci antineoplastici.     

Alcune significative pubblicazioni                                                                                                        

1. Toschi E, Sgadari C, Malavasi L, Bacigalupo I, Chiozzini C, Carlei D, Compagnoni D, Bellino S, Bugarini R, Falchi M, Palladino C, Leone P, Barillari G, Monini P, Ensoli B. Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via proteasome-independent block of angiogenesis and matrix metalloproteinases. Int. J. Cancer, 128: 82-93, 2011.

2. Barillari G, Franzese O, Comandini A, Bonmassar E,Ensoli B. Spindle cells from AIDS-associated Kaposi's sarcoma (KS) lesions express telomerase activity that is enhanced by KS progression factors. Oncol. Rep., 24 (1): 219-223, 2010.

3. Albonici L, Sorge RP, Santeusanio G, Garofano P, Manzari V, Barillari G. Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: a preliminary study. Oncol. Rep., 23: 1119-1123, 2010.

4. Barillari G, Franzese O, Iovane A and Ensoli B. Spindle cells from Acquired Immune Deficiency Syndrome (AIDS)-associated Kaposi’s sarcoma (KS) lesions express telomerase activity directly relating to the RNA levels of fibroblast growth factor (FGF)-2. Int. J. Cancer, 127: 2487-9, 2010.

5. Barillari G, Iovane A, Bonuglia M, Albonici L, Garofano P, Di Campli E, Falchi M, Condò I, Manzari V, Ensoli B.  Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: implications for atherogenesis. Atherosclerosis, 210 (2): 400-406, 2010.

6. Nappi F, Chiozzini C, Bordignon V, Borsetti A, Bellino S, Cippitelli M, Barillari G, Caputo A, Tyagi M, Giacca M, Ensoli B. Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation independent mechanism which requires binding of Tat to viral particles. J. Gene Med., 11 (11): 955-965, 2009.

7. Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone-Cossut MR, Scoglio A, Colacchi B, Nappi F, Macchia I, Bellino S, Francavilla V, Caputo A, Barillari G, Magnani M, Laguardia ME, Cafaro A, Titti F, Monini P, Ensoli F, Ensoli B. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J. Immunol. 182 (5): 2888-2897, 2009.

8. Monini P, Toschi E, Sgadari C, Bacigalupo I, Palladino C, Carlei D, Barillari G, and Ensoli B. The use of HAART for biological tumour therapy. J. HIV Ther., 11 (3): 53-6, 2006.

9. Toschi E, Bacigalupo I, Strippoli R, Cereseto A, Falchi M, Chiozzini C, Nappi F, Sgadari C,  Barillari G, Maniero F, and Ensoli B. HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. Mol. Biol. Cell, 17 (4): 1985-1994, 2006.

10. Monini P, Sgadari C, Toschi E, Barillari G and Ensoli B. Antitumour effects of antiretroviral  therapy. Nature Rev. Cancer, 4: 861-875, 2004.

11. Sgadari C, Monini P, Barillari G and Ensoli B. Use of HIV protease inhibitors to block Kaposi’s sarcoma and tumor growth. Lancet Oncol., 4: 537-547, 2003.

12. Barillari G, Sgadari C, Toschi E, Monini P and Ensoli B. HIV protease inhibitors as new treatment options for Kaposi’s sarcoma. Drug Resist. Updat., 6 (4): 173-181, 2003.

13. Monini P, Sgadari C, Barillari G, and Ensoli B. The HIV protease inhibitors: anti-retroviral agents with anti-inflammatory, anti-angiogenic and anti-tumor activity. J. Antimicrob. Chemother. 51 (2): 207-211, 2003.

14. Toschi E, Monini P, Barillari G, Bacigalupo I, Palladino C, Baccarini S, Carlei D, Grosso G, Sirianni MC and Ensoli B. Treatment of Kaposi’sarcoma: un update. Anticancer Drugs, 13: 977-987, 2002.

15. Barillari G and Ensoli B. Angiogenic effects of extracellular HIV-1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin. Microbiol. Rev., 15 (2): 310-326, 2002.

16. Ciafrè SA, Barillari G, Bongiorno Borbone L, Wannenes F, Izquierdo M and Farace MG. A tricistronic retroviral vector expressing natural antiangiogenic factors inhibits angiogenesis in vitro. Gene Ther., 9: 297-302, 2002.

17. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P and Ensoli B. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi’s sarcoma. Nat. Med., 8 (3): 225-232, 2002.

18. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A and Ensoli B. Native HIV-1 Tat protein is selectively taken up by monocyte-derived dendritic cells and induces their maturation, Th-1 cytokine production and antigen presenting function. J. Immunol., 168: 197-206, 2002.

19.Toschi E, Barillari G, Sgadari S, Bacigalupo I, Cereseto A, Carlei D, Palladino C, Zietz C, Leone P, Sturzl M, Buttò S, Cafaro A, Monini P and Ensoli B. Activation of MMP-2 and MT1-MMP in endothelial cells and induction of vascular permeability in vivo by the HIV-1 Tat protein and basic fibroblast growth factor. Mol. Biol. Cell., 12: 2934-2946, 2001

20. Guenzi E, Cornali E, Topolt K, Martellato C, Zietz C, Kremmer E, Nappi F, Schwemmle M, Hohenadl C, Jorg A, Matzen K, Barillari G, Tschachler E, Monini P, Ensoli B and Sturzl M. The guanylate binding protein-1 is the major intracellular regulator of the growth inhibition by inflammatory cytokines in endothelial cells. EMBO J., 20: 5568-5577, 2001

21. Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, Monini P. Biology of Kaposi's sarcoma. Eur. J. of Cancer, 37: 1251-1269, 2001.

22. Bussolino F, Mitola S, Serini G, Barillari G, Ensoli B. Interactions between endothelial cells and HIV-1. Int. J. Biochem. Cell Biol., 33: 371-390, 2001.

23. Barillari G, Albonici L, Incerpi S, Bogetto L, Pistritto G, Volpi A, Ensoli B and Manzari V. Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing a5b1 integrin expression and function. Atherosclerosis, 154: 377-385, 2001.

24. Sgadari C, Toschi E, Palladino C, Barillari G, Carlei D, Cereseto A, Ciccolella C, Yarchoan R, Monini P, Sturzl M, Ensoli B. Mechanism of paclitaxel activity in Kaposi's sarcoma. J. Immunol., 165: 509-517, 2000.

25. Barillari G, Sgadari C, Palladino C, Gendelman R, Caputo A, Bohan-Morris C, Nair BC, Markham P, Sturzl M and Ensoli B. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of bFGF and the avb3  integrin that are required for Tat activity. J. Immunol. 163: 1929-1935, 1999.

26. Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, Manzari V, Modesti A, Nair BC, Cafaro A, Sturzl M and Ensoli B. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the a5b1 and avb3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 94: 663-672, 1999.   

27. Fiorelli V, Barillari G, Sgadari C, Toschi E, Monini P, Sturzl M and Ensoli B. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to HIV-1 Tat. J. Immunol., 162: 1165-1170, 1999.

28. Pica F, Volpi A, Barillari G, Fraschetti M, Franzese O, Vullo V and Garaci E. Detection of high NGF serum levels in AIDS-related and -unrelated KS patients. AIDS 12: 7329-7334, 1998.

29. Barillari G, Albonici L, Franzese O, Modesti A, Liberati F, Barillari P, Ensoli B, Manzari V and Santeusanio G. The basic residues of PlGF-2 retrieve sequestered angiogenic factors into a soluble form. Am. J. Pathol., 152: 1161-1166, 1998.

30. Albini A, Barillari G, Benelli R, Gallo RC, and Ensoli B. Angiogenic properties of Human Immunedeficiency Virus type 1 Tat protein. Proc. Natl. Acad. Sci. USA 92: 4838-4842, 1995.       

31. Ensoli B, Markham P, Kao V, Barillari G, Fiorelli V, Gendelman R, Raffeld M, Zon G, and Gallo RC. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis and lesion formation in nude mice by antisense oligonucleotides tergeting basic fibroblast growth factor. J. Clin. Invest., 94: 1736-1746, 1994.

32. Barillari G, Gendelman R, Gallo RC, and Ensoli B. The Tat protein of HIV-1, a growth factor for AIDS-Kaposi's sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD sequence. Proc. Natl. Acad. Sci. USA 90: 7941-7945, 1993.

33. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, and Gallo RC.  Release, uptake and effects of extracellular Human Immunodeficiency Virus type-1 Tat protein on cell growth and viral transactivation. J. Virol. 67: 277-287, 1993.

34. Barillari G, Buonaguro L,  Fiorelli V, Hoffman J, Michaels F, Gallo RC, and Ensoli B.  Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. J. Immunol., 149: 3727-3734, 1992.

35. Buonaguro L, Barillari G, Chang HK, Bohan CA, Morgan RA, Kao V, Gallo RC, and Ensoli B. Effects of HIV-1 Tat protein on the expression of inflammatory cytokines. J. Virol.,  66: 7159-7167, 1992.

36. Ensoli B, Barillari G, and Gallo RC. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. In Moller, G. (Ed.) Immunol. Rev., 127: 147-155, 1992.

37. Ensoli B, Barillari G, and Gallo RC. Pathogenesis of AIDS-associated Kaposi's sarcoma. Hematol. Oncol. Clin. North Am. 5: 281-295, 1991.

38. Ensoli B, Barillari G, Buonaguro L and Gallo RC. Molecular mechanisms in the pathogenesis of AIDS-associated Kaposi's sarcoma. Adv. Exp. Med. Biol. 303: 27-38, 1991

39. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, and Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 344: 84-86, 1990.

40. Manzari V, Gismondi A, Barillari G, Morrone S, Modesti A, Albonici L, De Marchis L, Fazio VM, Gradilone A, Zani M, Frati L, and Santoni A. HTLV-V: a new human retrovirus isolated in a TAC-negative T-cell lymphoma/leukemia. Science 238: 1581-1583, 1987.

41. Manzari V, Barillari G, Albonici L, De Marchis L, and Frati L. Human T-lymphotropic infection in Italy. Ann. N.Y. Acad. Sci. 511: 401-405, 1987.

42. Gradilone A, Zani M, Barillari G, Modesti M, Aglianò AM, Maiorano G, Ortona L, Frati L, and Manzari V. HTLV-I and HIV-1 infection in drug addicts in Italy. Lancet: 753-754, 1986.

43. Pandolfi F, Semenzato G, De Rossi G, Barillari G, Napolitano M, Trentin L, Martelli M, Gradilone A, Cafaro A, Mandelli F, and Aiuti F. La leucemia linfatica cronica dei linfociti T. Ann. It. Med. Int., 1: 9-16, 1986.

44. Manzari V, Gradilone A, Barillari G, Zani M, Collalti E, Pandolfi F, De Rossi G, Liso V, Babbo P, Robert-Guroff M, and Frati L. HTLV-I is endemic in Southern Italy: detection of the first infectious cluster in a white population. Int. J. Cancer 36: 557-559, 1985.

45. Pandolfi F, Manzari V, De Rossi G, Semenzato G, Lauria F, Liso V, Ranucci A, Pizzolo G, Barillari G, and Aiuti F. T-helper phenotype chronic lymphocytic leukemia and adult T-cell leukemia in Italy. Lancet: 633-636, 1986.